Cardiome Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cardiome Pharma (CRME) Misses Q2 EPS by 18c
August 9, 2016 5:07 PM EDTCardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.37), $0.18 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $6.73 million.
For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.
... More